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OBJECTIVES This study evaluated the clinical and angiographic six-month follow-up after excimer laser
coronary angioplasty (ELCA) for restenosed coronary stents.
BACKGROUND Excimer laser coronary angioplasty has recently been shown to be safe and efficient for the
treatment of in-stent restenosis.
METHODS Ninety-six consecutive patients successfully treated with ELCA within 141 stents were
included in a six-month clinical and angiographic follow-up.
RESULTS During follow-up there was one sudden death and one patient with documented myocardial
infarction. Angina pectoris classified as $ Canadian Cardiovascular Society II reoccurred in
49 patients. Follow-up angiography was obtained in 89 patients (93%) with 133 stents.
Quantitative coronary angiography revealed a mean diameter stenosis of 77 6 10% before
intervention, 41 6 12% after laser treatment and 11% 6 12% after adjunctive percutaneous
transluminal coronary angioplasty (p , 0.001). Six months after ELCA the mean diameter
stenosis had increased to 60 6 26% (p , 0.001). A $50% diameter stenosis was present in
48 patients (54%); in 24 of these patients diameter stenosis was $70%. Total occlusions
occurred in an additional 10 patients (11%). There was a trend toward an increased recurrent
restenosis rate in patients with diabetes mellitus and long lesions or total occlusions (p 5
0.059). Forty-eight patients (50%) received medical treatment after six months. Reinterven-
tions were necessary in 30 patients (31%), and coronary artery bypass surgery was performed
in 17 patients (18%). Event-free survival was 50%.
CONCLUSIONS Excimer laser angioplasty for in-stent restenosis was associated with a high incidence of
recurrent restenosis in this group of patients, suggesting that this technique is unlikely to
reduce recurrent in-stent restenosis and that other approaches are necessary. (J Am Coll
Cardiol 2000;36:69–74) © 2000 by the American College of Cardiology
With the increasing use of coronary stents and the more
frequent implantation of stents into complex lesions, in-
stent restenosis has become a challenging problem in
interventional cardiology. The most frequently used tech-
nique to treat this new type of lesion is conventional balloon
angioplasty (1). However, previous studies have reported
angiographic restenosis rates up to 85% after repeat balloon
angioplasty of in-stent restenosis (2–7). Since the develop-
ment of recurrent restenosis may be related to a high
residual plaque burden and tissue reintrusion after repeat
balloon angioplasty, alternative techniques suitable to de-
bulk in-stent lesions have been evaluated (8). The first
debulking technique used within stents was directional
atherectomy; however, this method may cause stent wire
cutting and subsequent vessel occlusions with fatal clinical
outcomes in some patients (9–11). Rotational atherectomy
appears to be safer, and the long-term results are currently
under investigation (12–17). Excimer laser coronary angio-
plasty (ELCA) for the treatment of in-stent restenosis has
been shown to be safe and efficient in large series of patients
from different centers (18–20). However, the long-term
outcome remained to be investigated. This study was
designed to assess the clinical and angiographic six-month
results after treatment of in-stent restenosis with laser
followed by adjunctive balloon angioplasty.
METHODS
Patients. In this study 96 consecutive patients were pro-
spectively included. Written informed consent was obtained
from all patients under a protocol approved by the Ethics
Committee of the Hamburg Medical Board. The study was
carried out according to the principles of the Declaration of
Helsinki. Patients were included if they presented with an
in-stent restenosis or a wireable total occlusion within a
stent that had been implanted for .1 month into a native
vessel or a coronary artery vein graft. Patients with an
evolving myocardial infarction, angiographic evidence of
fresh thrombus or lesions in segments with major bifurca-
tions or curves .60° on visual assessment were excluded.
The mean age of the 96 patients was 60 6 10 years
(range: 29–76 years); 81 patients were men. Major coronary
risk factors were: diabetes mellitus (27 patients/28%) (non-
insulin dependent: n 5 20 (21%), insulin dependent: n 5 7
[7%]), hyperlipoproteinemia (72 patients/75%), arterial hy-
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pertension (63 patients/66%), current or recently stopped
smoking (53 patients/55%) and a positive family history for
coronary artery disease (37 patients/39%).
The patient group had a high prevalence of known risk
factors for recurrent restenosis (21–27). A previous or
current total occlusion was present in 23 patients (24%).
The stents had been implanted for recurrent restenosis in 20
patients (21%). In 14 patients stents were located in venous
bypass grafts (14%). Multiple stents ($2 stents/vessel) had
been implanted in 37 patients (39%). Stents were located in
small vessels (#3.00 mm in diameter) in 68 patients (71%).
Vessels treated and stent types. There were 25 patients
with single-vessel coronary artery disease (26%), 34 patients
with double-vessel disease (35%) and 37 patients with
triple-vessel disease (39%). There were 82 native vessels
treated. These vessels were 42 left anterior descending, 16
left circumflex and 24 right coronary arteries. Fourteen vein
grafts were treated.
Excimer laser angioplasty was performed within 141 coro-
nary stents (77 AVE stents [Applied Vascular Engineering,
Santa Rosa, California], 46 Palmaz-Schatz stents [Johnson
& Johnson, Warren, New Jersey], 6 NIR stents [Boston
Scientific, Galway, Ireland], 3 beStent stents [Medtronic
Instent, Herzlia, Israel], 3 Multilink stents [Guidant/
Advanced Cardiovascular Systems, Temecula, California],
1 Wiktor stent [Medtronic, Minneapolis, Minnesota], 5
others).
The majority of stents was of modular design (n 5 77);
63 were slotted tube stents, and one stent was of coil design.
There were 37 patients with $2 stents/vessel. The stents
had been implanted for 6 6 3 months (range: 2–16 months)
before the time of intervention.
Excimer laser system and adjunctive balloon angioplasty.
A xenon chloride excimer laser unit operating at a wave-
length of 308 nm (Spectranetics CVX-300, Colorado
Springs, Colorado) was used in all patients. The laser unit
delivered laser pulses of 135 ns pulse duration at a frequency
(repetition rate) of 25 to 40 Hz and an energy density
(fluence) of 30 to 60 mJ/mm2. The laser energy was
delivered through concentric (n 5 40) or eccentric (n 5 56)
multifiber laser catheters (Vitesse CII or Vitesse EII;
Spectranetics Corp., Colorado Springs, Colorado) with tips
1.4, 1.7 or 2.0 mm in diameter. Of the eccentric catheters,
38 were 1.7 mm, and 18 were 2.0 mm in diameter.
Intracoronary saline infusion was initiated 3 s before deliv-
ery of laser energy and was continued during excimer laser
treatment. Multiple passes, especially with the eccentric
catheter, were performed at the operator’s discretion to
achieve maximum debulking. Adjunctive balloon angio-
plasty was performed in all patients using standard tech-
niques.
Medical treatment before, during and after ELCA. Pre-
treatment medication consisted of oral aspirin 100 mg/day
(or 300 mg aspirin, if the patient was not on aspirin therapy
before). A standard angioplasty regimen of heparin
(10.000 IU intravenous bolus injection) and intracoronary
nitroglycerin (100 mg to 200 mg) was given before angio-
graphy was performed. The permanent medical treatment
after the intervention consisted of oral aspirin 100 mg/day.
Quantitative coronary angiography. All angiograms were
evaluated by an independent blinded investigator on a
Kontron Cardio 500 workstation for computerized quanti-
tative coronary angiography with an automated contour
detection (Kontron Electronics, Eching, Germany) and
were adjusted by manual correction if necessary as described
previously (19). Angiographic analysis of cinefilms was
performed before laser treatment, after laser treatment, after
adjunctive balloon angioplasty and at follow-up in the same
projections. The coronary flow was classified according to
the Thrombolysis in Myocardial Infarction (TIMI) trial
classification (28).
Clinical follow-up. Clinical evaluation at six-month
follow-up included the record of cardiac adverse events and
clinical symptoms defined as: death (death for cardiac or any
other cause), myocardial infarction (ST segment elevation
$0.10 mV in $2 electrocardiographic leads plus creatine
kinase elevation $2 times above normal value associated
with .6% creatine kinase MB fraction or the development
of new pathologic Q waves in the electrocardiogram accord-
ing to the Minnesota Code [29]). At this time the occur-
rence of angina pectoris, graded according to the classifica-
tion of the Canadian Cardiovascular Society (CCS) (30),
was registered.
Statistical analysis. All data are presented as mean 6
standard deviation unless otherwise stated. Continuous
variables were compared by the paired Student t test. The
association between two quantitative variables was charac-
terized by the correlation coefficient. The Fisher exact test
was used to compare proportions. For simply ordered
contingency tables, the Kruskal-Wallis test was used. A
probability of ,0.05 was considered to be statistically
significant.
RESULTS
Clinical follow-up. The acute results limited to the in-
hospital safety and feasibility of the technique from a
subgroup were reported previously (19). It has been shown
that angiographic success (diameter stenosis ,50%) was
achieved in all patients if the lesion could be crossed with a
guidewire (19). Eleven percent of the patients had dissec-
tions (1% related to laser treatment, 10% to adjunctive
percutaneous transluminal coronary angioplasty [PTCA]);
Abbreviations and Acronyms
CCS 5 Canadian Cardiovascular Society
ELCA 5 excimer laser coronary angioplasty
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction (trial)
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1.4% of the patients had laser related perforations (19).
There was no Q wave infarction and no death (19).
During follow-up there was one patient with myocardial
infarction leading to hospital admission (1%). One patient
with history of current smoking died from sudden death at
home approximately one week after the intervention (1%).
The cause of death remained undefined since autopsy was
not performed. A sudden cardiac death appears to be likely
since the patient suffered from no other obvious disorders.
During follow-up 7 patients had angina pectoris graded
as CCS class I (7%), 20 patients were graded as class II
(21%), 21 patients as class III (22%) and 8 patients as class
IV (8%). The overall rate of patients with recurrent angina
was 58%.
Twenty-four patients had to undergo repeat cardiac
catheterization for recurrent angina pectoris earlier as orig-
inally scheduled. In these patients angiography had to be
performed 2.7 6 0.9 months earlier. Twenty of these
patients were treated interventionally at the site of the
previously lasered target lesion.
Quantitative coronary angiography. Follow-up coronary
repeat angiography was obtained in 89 of 96 patients (93%).
One patient died before repeat angiography; the other six
patients refused to undergo a control angiography because
they were completely asymptomatic.
The mean reference diameter of the treated vessels was
2.84 6 0.38 mm before intervention (n 5 89 patients). The
percentage diameter stenosis before intervention was 77 6
10% and was reduced to 41 6 12% by laser treatment (p ,
0.001) (39 6 11% in vessels ,3.00 mm in diameter, 45 6
9% in vessels $3.00 mm in diameter). Adjunctive balloon
angioplasty further reduced diameter stenosis to 11 6 12%
(p , 0.001). At six-month follow-up the average diameter
stenosis had increased to 60 6 26% (p , 0.001) (Fig. 1).
The overall angiographic binary restenosis ($50% diameter
stenosis) rate was 65%.
There were 24 patients with a moderate degree of
restenosis between 50% and 69% and 24 patients with a
high grade of restenosis between 70% and 99%. In addition,
there were 11 patients presenting with total occlusions.
The average lesion length before intervention was 16 6
9 mm (six total occlusions not included). At the time of
repeat angiography, it was 17 6 10 mm (10 total occlusions
not included). Before intervention, the majority of patients
had long lesions .10 mm. The incidence of recurrent
restenosis in patients with long lesions tended to be higher
than in patients with short lesions; however, this difference
was not statistically significant (Table 1). In the group with
total occlusions (n 5 6), four patients had a recurrent
restenosis, and two patients presented with a recurrent total
occlusion.
Figure 1. Percentage of diameter stenosis measured by quantitative coro-
nary angiography before intervention (D), after excimer laser treatment ({),
after adjunctive balloon angioplasty (1) and at six-month follow-up (3) in
89 patients. The percentage of diameter stenosis decreased significantly
after laser treatment and further after adjunctive balloon angioplasty (p ,
0.001). At follow-up there was a significant late lumen loss which
translated into an increase of diameter stenosis (p , 0.001).
Table 1. Angiographic Recurrent Restenosis Rates After Laser
Angioplasty in 89 Patients With Different Lesion Length and
Residual Stenosis After Ablation, Treatment With Different
Types of Catheters and Catheter/Vessel Ratios and Different










#10 mm 22 12 (55%) 0.34
.10 mm 67 46 (69%)
Residual stenosis after laser
,30% 9 4 (44%) 0.17
$30% 80 54 (68%)
Diameter of laser catheter
1.4 mm 2 2 (100%)
1.7 mm 46 27 (59%) 0.45
2.0 mm 41 28 (68%)
Type of catheter
Concentric 39 26 (67%) 0.82
Eccentric 50 31 (62%)
Catheter/vessel ratio
0.45–0.69 67 43 (64%) 0.92
0.70–0.95 22 15 (68%)
Stent location
Vein graft 13 8 (62%) 0.92
Native vessel 76 51 (67%)
Vessel diameter
,3.00 mm 63 39 (62%) 0.45
$3.00 mm 26 19 (73%)
Final minimal lumen diameter
after balloon angioplasty
#2.50 mm 38 29 (76%)
.2.50–3.00 mm 40 22 (55%) 0.10*
.3.00 mm 11 6 (55%)
Stent number/vessel
$2 stents 38 23 (61%) 0.83
single 51 34 (67%)
History of previous or current
total occlusion
Yes 21 13 (62%) 0.99
No 68 43 (63%)
*#2.50 mm vs. .2.50–3.00 mm: 76% vs. 55%, p 5 0.045.
71JACC Vol. 36, No. 1, 2000 Ko¨ster et al.
July 2000:69–74 Six-Month Results of Laser Angioplasty for In-Stent Restenosis
Patients with a low degree of residual diameter stenosis
after the laser ablation (,30%) had no significantly different
rate of binary restenosis compared with patients with a
higher degree of residual stenosis (Table 1). However, in
this small subgroup of patients, there was a tendency
towards a lower restenosis rate if the residual diameter
stenosis after laser debulking was lower than 30%. Aggres-
sive debulking with a large gain of minimal lumen diameter
(MLD) after laser treatment correlated positively with a
large lumen diameter gain after adjunctive PTCA (r 5
0.815; p , 0.001). A large MLD after final PTCA
correlated positively with a large MLD at six-month
follow-up (r 5 0.347, p , 0.001) and correlated inversely
with the degree of diameter restenosis (r 5 20.229, p 5
0.031).
Treatment with larger laser catheters resulted in a larger
post-laser MLD (1.4 mm: 1.14 6 0.30 mm; 1.7 mm:
1.59 6 0.21 mm; 2.0 mm: 1.88 6 0.17 mm; p , 0.01) and
lower diameter stenosis (1.4 mm: 61 6 13%; 1.7 mm: 42 6
9%; 2.0 mm: 39 6 13%; p , 0.04). However, treatment
with laser catheters of different diameters was not followed
by a significant difference in recurrent restenosis rates (Table
1). If the eccentric types of laser catheters were used, there
was a tendency towards a lower recurrent restenosis rate;
however, the difference was not statistically significant
(Table 1). A high catheter to vessel ratio ($0.7) had no
beneficial effect on restenosis rates (Table 1).
The mean number of passes with the laser catheter was
5 6 3. More passes with the laser catheter did not
significantly increase the MLD (#4 passes: 1.73 6
0.23 mm; 5–8 passes: 1.73 6 0.28 mm: .8 passes: 1.72 6
0.18 mm: p . 0.83) or further decrease the diameter
stenosis. There was no difference in recurrent restenosis
rates after different numbers of passes (#4 vs. 5–8 vs. $9)
with the laser catheters (p . 0.05). This result was observed
after the use of concentric catheters and after the use of
eccentric catheters. The mean energy density (fluence) used
as 46 6 4 mJ/mm2. The mean balloon pressure was 11 6
4 atm.
The prevalence of recurrent restenosis in the subgroup of
patients with stents located in bypass vein grafts was not
significantly different from that in patients with stents
located in native vessels (Table 1).
Patients with small vessel diameters (,3 mm) and those
in a small group with large vessel diameters ($3 mm) had
no significantly different restenosis rates (Table 1).
The restenosis rate of patients with multiple stents was
not significantly different from that of patients with single
stent implantation (Table 1).
The group with a history of previous or current total oc-
clusion had a recurrent restenosis rate comparable with that
in the group without a history of total occlusion (Table 1).
Patients with risk factors for coronary artery disease such
as hyperlipoproteinemia, arterial hypertension, smoking,
positive family history or diabetes mellitus had no signifi-
cantly increased restenosis rates compared with groups
without the respective factors (p $ 0.05 for each factor)
(Table 2). Patients with diabetes mellitus who presented
with long lesions tended to have high recurrent restenosis
rate (lesion # 10 mm, 7 patients: 43% restenosis rate; lesion
11–20 mm, 14 patients: 71% restenosis; lesion .20 mm, 5
patients: 100% restenosis, p 5 0.059).
The coronary flow before intervention was classified as
TIMI 0 in 6 patients (6%) with total occlusions, TIMI 1 in
4 patients (4%), TIMI 2 in 10 patients (11%) and TIMI 3
in 76 patients (79%). At the time of control angiography,
TIMI flow was graded as 0 in 10 patients (11%), TIMI 1 in
3 patients (3%), TIMI 2 in 4 patients (5%) and TIMI 3 in
72 patients (81%).
Treatment after six-month follow-up. At six-month
follow-up half of the patients received medical treatment
(n 5 48); the other patients required reinterventions.
Seventeen patients were treated by coronary artery bypass
surgery (18%). Recurrent balloon angioplasty was per-
formed in 11 patients (11%), recurrent ELCA was done in
6 patients (6%), and rotational atherectomy was performed
in 13 patients (14%). The choice of the technique at the
time of follow-up was left to the operator.
The event-free survival rate without coronary reinterven-
tion in the whole study group was 50%.
DISCUSSION
There is an increasing need to evaluate techniques other
than balloon angioplasty to treat in-stent restenosis. Exci-
mer laser angioplasty has recently been shown to be safe and
efficient for the treatment of this type of lesion (18–20). It
has been demonstrated that laser angioplasty achieves ex-
cellent acute angiographic results (18–20). The long-term
results of the technique remained to be analyzed. This
report describes a large series of patients treated with ELCA
for in-stent restenosis who were followed-up clinically and
angiographically.
Table 2. Recurrent Restenosis Six Months After Excimer









Hyperlipoproteinemia 68 45 (66%) 0.91
No hyperlipoproteinemia 21 13 (62%)
Diabetes mellitus 26 18 (69%) 0.79
No diabetes mellitus 63 40 (63%)
Arterial hypertension 60 43 (72%) 0.05
No arterial hypertension 29 15 (52%)
Smoking 49 34 (69%) 0.24
No smoking 40 24 (60%)
Positive family history 35 21 (60%) 0.72
No positive family history 54 37 (69%)
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Clinical results. This study showed only limited clinical
long-term success since more than half of the patients had
recurrent symptoms of angina pectoris during the follow-up
period. This necessitated earlier angiographic controls as
scheduled in 25% of the patients, followed by a considerable
number of target vessel revascularizations. The incidence of
myocardial infarctions and deaths was low and comparable
with the rate after plain balloon angioplasty within the stent
(2–7).
Angiographic results. The angiographic results were un-
satisfactory. There was a significant lumen late loss at the
six-month follow-up angiographic control, which led to an
average diameter stenosis of 60% corresponding to a binary
restenosis rate of 65%. The recurrent restenosis rate ap-
peared to be higher in long compared with short lesions,
particularly in diabetic patients, and was extremely high in
the small group of patients who were treated for total
occlusions within a stent. The high incidence of recurrent
restenosis in patients presenting with an in-stent occlusion
is in good agreement with data from a recently published
report that showed a need for target vessel revascularization
in 83% of patients with total in-stent occlusions, regardless
of the device used (25).
The angiographic restenosis rate was high, but there was
a relatively large subgroup of 24 patients with moderate
grade restenosis with a diameter stenosis between 50 and
69%. These patients had, in fact, an angiographic restenosis
by the binary definition; however, this restenosis has neither
been hemodynamically relevant nor did it necessarily require
reintervention in most patients.
The incidence of restenosis in small vessels below 3 mm
in diameter appeared similar to that in larger vessels with
diameters above 3 mm. Previous studies have suggested that
the restenosis rate after treatment of in-stent restenosis
tends to be higher in smaller vessels (21,23). With respect to
these previous findings, the result in this study seems to be
surprising but may be explained by random distribution or
by the fact that in smaller vessels a larger proportion of
plaque mass might have been ablated.
The high rate of restenosis may partially be explained by
the cautious approach to ablation in this study. Most
aggressive debulking in a subgroup of patients with low
residual stenosis after laser treatment (,30%) was associ-
ated with a lower restenosis rate than seen in patients with
a higher degree of residual stenosis after laser treatment.
However, the finding in this small group did not reach
statistical significance and needs to be evaluated in a larger
series. Due to the cautious use of laser angioplasty and the
use of relatively small catheters in this study, the mean
diameter stenosis after debulking was as high as 41%. This
degree of diameter stenosis may also reflect a lack of efficacy
of excimer laser treatment, which has been suggested by
previous studies and may be related to a limited ability of the
technique to ablate tissue (31,32).
The patients of this study group had multiple risk factors
for the development of restenosis such as previous total
occlusions, multiple stenting or stent location in bypass
grafts (21,22,24). Although a significant impact on the
recurrence of restenosis could not be documented for any of
these single factors, the high total incidence of multiple risk
factors in this group might have negatively influenced the
outcome of these patients and may contribute to an under-
estimation of the value of the technique.
The rate of restenosis in this group is high; however, it
appears to be comparable with recent results with other
debulking techniques such as rotational atherectomy with
restenosis rates up to 78% in diffuse lesions (15,33) if the
risk profile in this group is taken into account. The results
of this study do not appear to be favorable compared with
the results from recently evaluated alternative methods such
as stenting for in-stent restenosis with a restenosis rate
between 46% and 72% (34,35).
Study limitations. This study was not randomized, and
there was no comparison with conventional balloon angio-
plasty. Six patients refused repeat angiography; however, all
of these six patients were asymptomatic and, therefore,
likely to have either a low degree of restenosis or no
restenosis at all. Therefore, the exclusion of these 6% of the
patients, who had a favorable outcome, might have nega-
tively influenced our analysis of the restenosis rate.
Although, to our knowledge, this is the largest series of
patients lasered in stents with systematic angiographic
follow-up yet, the number of patients in this study was still
relatively low. This is particularly important for the sub-
group analyses, in which various trends have been detected,
which may become significant in larger series. Therefore,
larger studies have to be performed to confirm these
findings.
Conclusions, clinical implications and future prospects.
In summary, the clinical and angiographic long-term out-
come of patients in this group with an exceptional high risk
of restenosis is not satisfactory yet. Since there was no
convincing evidence that patients with aggressive laser
treatment had an improved long-term outcome, the value of
the laser as a debulking tool remains questionable. However,
it appears to be too early to make a final assessment
regarding the value of this technique since there may be
benefits by its use in subsets of lesions.
Some reports about conventional balloon angioplasty and
debulking techniques revealed lower restenosis rates than
achieved in our group; others showed higher restenosis rates
(2–7,25). Different results were obtained after PTCA of
“discrete” and “diffuse” in-stent restenoses with better long-
term outcome after treatment of “discrete” lesions (2–7,25).
However, there is a considerable variation in the published
results and in the angiographic follow-up rates. To analyze
whether PTCA alone or ELCA is associated with a lower
recurrent restenosis rate, it is necessary to compare the
outcome after use of both techniques in a randomized trial,
particularly with respect to lesion length and morphology.
However, the data of this study suggest the limitation of a
randomized trial to patients without diffuse lesions and
73JACC Vol. 36, No. 1, 2000 Ko¨ster et al.
July 2000:69–74 Six-Month Results of Laser Angioplasty for In-Stent Restenosis
diabetes because the restenosis rate in this subgroup appears
to be unacceptably high.
Further development of the laser technology with the use
of larger catheters may be considered for the future. Other
options that have to be considered are adjunctive medical
therapy or intravascular brachytherapy. These treatment
modalities have the potential to inhibit tissue growth in the
lesion and may preserve the acute results of laser angioplasty
(36–38).
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